The cross talk between microbiota and the immune system: Metabolites take center stage

Current Opinion in Immunology

Volumn 30, Issue 1, 2014, Pages 54-62

  Shapiro, Hagit ^a   Thaiss, Christoph A ^a   Levy, Maayan ^a   Elinav, Eran ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGINASE 1; ARGININE; ASCORBIC ACID; BILE ACID; CARNITINE; CYANOCOBALAMIN; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONG CHAIN FATTY ACID; MITOGEN ACTIVATED PROTEIN KINASE 3; POLYSACCHARIDE; RETINOL; SHORT CHAIN FATTY ACID; VITAMIN; VITAMIN B GROUP; FATTY ACID;

BACTERIAL CELL; BACTERIAL METABOLISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMOTAXIS; DIET; DYSBIOSIS; ENZYME INHIBITION; FERMENTATION; FOOD COMPOSITION; GASTROINTESTINAL TRACT; HUMAN; IDIOPATHIC DISEASE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREACTIVITY; INNATE IMMUNITY; INTESTINE FLORA; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; VITAMIN DEFICIENCY; ANIMAL; IMMUNOLOGY; MICROFLORA; AMINO ACID SEQUENCE; BACTERIAL TRANSMISSION; COMPLEX FORMATION; CYTOKINE PRODUCTION; DEVELOPMENTAL STAGE; DIETARY INTAKE; FATTY ACID METABOLISM; HOST PATHOGEN INTERACTION; IMMUNOREGULATION; LIPID COMPOSITION; MICROBIAL METABOLISM; PROTEIN PROTEIN INTERACTION;

ANIMALS; BILE ACIDS AND SALTS; FATTY ACIDS; HUMANS; IMMUNE SYSTEM; MICROBIOTA; POLYSACCHARIDES; VITAMINS;

EID: 84904892129     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.07.003     Document Type: Review

References (114)

1. Sommer F., Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013, 11:227-238.
2. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
3. Thaiss C.A., et al. The interplay between the innate immune system and the microbiota. Curr Opin Immunol 2014, 26:41-48.
4. David L.A., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505:559-563.
5. Maslowski K.M., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
6. Smith P.M., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013, 341:569-573.
7. Arpaia N., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504:451-455.
8. Chang P.V., et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 2014, 111:2247-2252.
9. Singh N., et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014, 40:128-139.
10. Elinav E., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
11. Allen I.C., et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010, 207:1045-1056.
12. Salcedo R., et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010, 207:1625-1636.
13. Zaki M.H., et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.
14. Donohoe D.R., et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011, 13:517-526.
15. Trompette A., et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014, 20:159-166.
16. Lee J.H., et al. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. Nat Rev Cardiol 2009, 6:753-758.
17. Devillard E., et al. Metabolism of linoleic acid by human gut bacteria: different routes for biosynthesis of conjugated linoleic acid. J Bacteriol 2007, 189:2566-2570.
18. Gorissen L., et al. Production of conjugated linoleic acid and conjugated linolenic acid isomers by Bifidobacterium species. Appl Microbiol Biotechnol 2010, 87:2257-2266.
19. Mcintosh F.M., et al. Mechanism of conjugated linoleic acid and vaccenic acid formation in human faecal suspensions and pure cultures of intestinal bacteria. Microbiology 2009, 155:285-294.
20. Wall R., et al. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr 2009, 89:1393-1401.
21. Kishino S., et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc Natl Acad Sci U S A 2013, 110:17808-17813.
22. Gudbrandsen O.A., et al. Trans-10,cis-12-conjugated linoleic acid reduces the hepatic triacylglycerol content and the leptin mRNA level in adipose tissue in obese Zucker fa/fa rats. Br J Nutr 2009, 102:803-815.
23. Toomey S., et al. Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis 2006, 187:40-49.
24. Itoh T., et al. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 2008, 15:924-931.
25. Moya-Camarena S.Y., et al. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha. J Lipid Res 1999, 40:1426-1433.
26. Are A., et al. Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells. Proc Natl Acad Sci U S A 2008, 105:1943-1948.
27. Kelly D., et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004, 5:104-112.
28. Ridlon J.M., Kang D.J., Hylemon P.B. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006, 47:241-259.
29. Thomas C., et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008, 7:678-693.
30. Chiang J.Y. Bile acids: regulation of synthesis. J Lipid Res 2009, 50:1955-1966.
31. Midtvedt T. Microbial bile acid transformation. Am J Clin Nutr 1974, 27:1341-1347.
32. Claus S.P., et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 2008, 4:p219.
33. Kuribayashi H., et al. Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. Eur J Pharmacol 2012, 697:132-138.
34. Sayin S.I., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013, 17:225-235.
35. Swann J.R., et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A 2011, 108(Suppl. 1):4523-4530.
36. Inagaki T., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006, 103:3920-3925.
37. Ridaura V.K., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341:1241214.
38. Yoshimoto S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
39. Vavassori P., et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009, 183:6251-6261.
40. Wang Y.D., et al. The G-protein-coupled bile acid receptor Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 2011, 54:1421-1432.
41. Pols T.W., et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011, 14:747-757.
42. Wen A.Y., Sakamoto K.M., Miller L.S. The role of the transcription factor CREB in immune function. J Immunol 2010, 185:6413-6419.
43. Mcmahan R.H., et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013, 288:11761-11770.
44. Gadaleta R.M., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60:463-472.
45. Mencarelli A., et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 2009, 183:6657-6666.
46. -/- mice. Nature 2012, 487:104-108.
47. Mazmanian S.K., et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005, 122:107-118.
48. Mazmanian S.K., Round J.L., Kasper D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-625.
49. Round J.L., et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011, 332:974-977.
50. Lee Y.K., et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2011, 108(Suppl. 1):4615-4622.
51. Ochoa-Reparaz J., et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J Immunol 2010, 185:4101-4108.
52. Hsiao E.Y., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013, 155:1451-1463.
53. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35:427-433.
54. Fendt S.M., et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 2013, 73:4429-4438.
55. Metallo C.M., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481:380-384.
56. Harvey R.J., Yee B.K. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 2013, 12:866-885.
57. Munn D.H., et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999, 189:1363-1372.
58. Hashimoto T., et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012, 487:477-481.
59. Puccetti P., Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007, 7:817-823.
60. Zelante T., et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013, 39:372-385.
61. Lee J.S., et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol 2012, 13:144-151.
62. Qiu J., et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 2012, 36:92-104.
63. Favre D., et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010, 2. 32ra36.
64. Huengsberg M., et al. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem 1998, 44:858-862.
65. Desvignes L., Ernst J.D. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 2009, 31:974-985.
66. Romani L., et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008, 451:211-215.
67. Sandler N.G., Douek D.C. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012, 10:655-666.
68. Morris S.M. Arginine metabolism: boundaries of our knowledge. J Nutr 2007, 137(Suppl. 2):1602S-1609S.
69. Zhu X., Herrera G., Ochoa J.B. Immunosupression and infection after major surgery: a nutritional deficiency. Crit Care Clin 2010, 26:491-500. ix.
70. Barbul A. Arginine and immune function. Nutrition 1990, 6:53-58. (discussion 59-62).
71. Rodriguez P.C., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004, 64:5839-5849.
72. Munder M., et al. Suppression of T-cell functions by human granulocyte arginase. Blood 2006, 108:1627-1634.
73. Koeth R.A., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013, 19:576-585.
74. Hill M.J. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 1997, 6(Suppl. 1):S43-S45.
75. Martens J.H., et al. Microbial production of vitamin B12. Appl Microbiol Biotechnol 2002, 58:275-285.
76. Roth J.R., Lawrence J.G., Bobik T.A. Cobalamin (coenzyme B12): synthesis and biological significance. Annu Rev Microbiol 1996, 50:137-181.
77. Strozzi G.P., Mogna L. Quantification of folic acid in human feces after administration of Bifidobacterium probiotic strains. J Clin Gastroenterol 2008, 42(Suppl. 3):S179-S184.
78. Noda H., Akasaka N., Ohsugi M. Biotin production by bifidobacteria. J Nutr Sci Vitaminol (Tokyo) 1994, 40:181-188.
79. Pompei A., et al. Folate production by bifidobacteria as a potential probiotic property. Appl Environ Microbiol 2007, 73:179-185.
80. Kleerebezem M., Vaughan E.E. Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. Annu Rev Microbiol 2009, 63:269-290.
81. Spencer S.P., et al. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science 2014, 343:432-437.
82. Rahmathullah L., et al. Reduced mortality among children in southern India receiving a small weekly dose of vitamin A. N Engl J Med 1990, 323:929-935.
83. Hall J.A., et al. The role of retinoic acid in tolerance and immunity. Immunity 2011, 35:13-22.
84. Ertesvag A., et al. Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion. J Immunol 2002, 169:5555-5563.
85. Ertesvag A., et al. Vitamin A potentiates CpG-mediated memory B-cell proliferation and differentiation: involvement of early activation of p38MAPK. Blood 2007, 109:3865-3872.
86. Semba R.D. The role of vitamin A and related retinoids in immune function. Nutr Rev 1998, 56:S38-S48.
87. Yang Y., et al. Effects of vitamin A deficiency on mucosal immunity and response to intestinal infection in rats. Nutrition 2011, 27:227-232.
88. Butera S.T., Krakowka S. Assessment of lymphocyte function during vitamin A deficiency. Am J Vet Res 1986, 47:850-855.
89. Pasatiempo A.M., et al. Antibody production in vitamin A-depleted rats is impaired after immunization with bacterial polysaccharide or protein antigens. FASEB J 1990, 4:2518-2527.
90. Smith S.M., Hayes C.E. Contrasting impairments in IgM and IgG responses of vitamin A-deficient mice. Proc Natl Acad Sci U S A 1987, 84:5878-5882.
91. Yang Y., Vacchio M.S., Ashwell J.D. 9-Cis-retinoic acid inhibits activation-driven T-cell apoptosis: implications for retinoid X receptor involvement in thymocyte development. Proc Natl Acad Sci U S A 1993, 90:6170-6174.
92. Iwata M., et al. Retinoic acids inhibit activation-induced apoptosis in T cell hybridomas and thymocytes. J Immunol 1992, 149:3302-3308.
93. Wiedermann U., et al. Vitamin A deficiency predisposes to Staphylococcus aureus infection. Infect Immun 1996, 64:209-214.
94. Iwata M., et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004, 21:527-538.
95. Rojanapo W., Lamb A.J., Olson J.A. The prevalence, metabolism and migration of goblet cells in rat intestine following the induction of rapid, synchronous vitamin A deficiency. J Nutr 1980, 110:178-188.
96. Cha H.R., et al. Downregulation of Th17 cells in the small intestine by disruption of gut flora in the absence of retinoic acid. J Immunol 2010, 184:6799-6806.
97. Kang S.G., Vitamin A., et al. metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol 2007, 179:3724-3733.
98. + T cell effector responses via retinoic acid receptor alpha. Immunity 2011, 34:435-447.
99. + T cell-mediated immunity. J Exp Med 2011, 208:1767-1775.
100. Tokuyama Y., Tokuyama H. Retinoids as Ig isotype-switch modulators. The role of retinoids in directing isotype switching to IgA and IgG1 (IgE) in association with IL-4 and IL-5. Cell Immunol 1996, 170:230-234.
101. Jaensson E., et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med 2008, 205:2139-2149.
102. Mora J.R., et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006, 314:1157-1160.
103. Wang S., et al. MyD88-dependent TLR1/2 signals educate dendritic cells with gut-specific imprinting properties. J Immunol 2011, 187:141-150.
104. + T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment. Clin Exp Immunol 1999, 116:28-32.
105. Kunisawa J., et al. A pivotal role of vitamin B9 in the maintenance of regulatory T cells in vitro and in vivo. PLOS ONE 2012, 7:e32094.
106. Kjer-Nielsen L., et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012, 491:717-723.
107. Le Bourhis L., Mburu Y.K., Lantz O. MAIT cells, surveyors of a new class of antigen: development and functions. Curr Opin Immunol 2013, 25:174-180.
108. von Essen M.R., et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010, 11:344-349.
109. Sun J. Vitamin D and mucosal immune function. Curr Opin Gastroenterol 2010, 26:591-595.
110. Abreu M.T., et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004, 53:1129-1136.
111. Wada K., et al. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 2009, 22:1021-1025.
112. Sander L.E., et al. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 2011, 474:385-389.
113. Deriu E., et al. Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe 2013, 14:26-37.
114. Maier L., et al. Microbiota-derived hydrogen fuels salmonella typhimurium invasion of the gut ecosystem. Cell Host Microbe 2013, 14:641-651.